
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy IND clearance follows the granting of European Medicine Agency (EMA) orphan drug designation in April 2025 First patient …